Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 1/2015

01-01-2015 | Letter

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units

Authors: Anne-Claire Toffart, Xavier Dhalluin, Nicolas Girard, Christos Chouaid, Clarisse Audigier-Valette, Michaël Duruisseaux, Bertrand Mennecier, Antoine Parrot, Pierre Fournel, Denis Moro-Sibilot, Jean-François Timsit

Published in: Intensive Care Medicine | Issue 1/2015

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRef
2.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394PubMedCrossRef
3.
Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K (2013) Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 8:250–253PubMedCrossRef
4.
van Geffen WH, Hiltermann TJ, Groen HJ (2013) Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. J Thorac Oncol 8:e1–e2PubMedCrossRef
5.
Toffart AC, Minet C, Raynard B, Schwebel C, Hamidfar-Roy R, Diab S, Quetant S, Moro-Sibilot D, Azoulay E, Timsit JF (2011) Use of intensive care in patients with nonresectable lung cancer. Chest 139:101–108PubMedCrossRef
Metadata
Title
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units
Authors
Anne-Claire Toffart
Xavier Dhalluin
Nicolas Girard
Christos Chouaid
Clarisse Audigier-Valette
Michaël Duruisseaux
Bertrand Mennecier
Antoine Parrot
Pierre Fournel
Denis Moro-Sibilot
Jean-François Timsit
Publication date
01-01-2015
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 1/2015
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-014-3535-x

Other articles of this Issue 1/2015

Intensive Care Medicine 1/2015 Go to the issue

Understanding the Disease

Understanding the HPA response to critical illness: novel insights with clinical implications

Correspondence

Unsolved questions in solid tumor patients and intensive care: response to Vincent et al.

What's New in Intensive Care

What’s new in subarachnoid hemorrhage

Editorial

Mortality is the only relevant outcome in ARDS: no

Pediatric Original

Pulse oximetry vs. PaO2 metrics in mechanically ventilated children: Berlin definition of ARDS and mortality risk

Correspondence

What is “severe burnout” and can its prevalence be assessed?